Compugen Reports Strong FY2025 Results, Secures $65M Non-Dilutive Funding, Extends Cash Runway to 2029

summarizeSummary

Compugen Ltd. reported a significant financial turnaround in fiscal year 2025, achieving net profit and substantially increasing its cash position, bolstered by a $65 million non-dilutive payment from AstraZeneca, extending its cash runway into 2029.

check_boxKey Events

• Strong Financial Performance

  Compugen achieved a net profit of $35.3 million in 2025, a significant improvement from net losses of $14.2 million in 2024 and $18.8 million in 2023. Revenues increased substantially to $72.8 million in 2025 from $27.9 million in 2024.

• Secured $65M Non-Dilutive Funding

  The company received a $65 million upfront payment in December 2025 from AstraZeneca by selling a portion of its existing royalty interest in rilvegostomig, a PD-1/TIGIT bispecific antibody derived from Compugen's COM902 program.

• Extended Cash Runway

  Compugen projects its current cash, cash equivalents, short-term bank deposits, and marketable securities will be sufficient to fund operations into 2029, without considering additional financing.

• TIGIT Program (COM902) Update

  Due to recent negative data in the broader TIGIT field, the company believes its COM902 program has limited near-term value and does not plan to initiate new clinical trials for this anti-TIGIT antibody.

auto_awesomeAnalysis

Compugen Ltd. reported a significant financial turnaround for fiscal year 2025, achieving a net profit of $35.3 million compared to losses in previous years, with revenues climbing to $72.8 million. This strong performance was significantly bolstered by a $65 million upfront payment received in December 2025 from AstraZeneca, stemming from an amendment to their license agreement where Compugen sold a portion of its future royalty interest in rilvegostomig. This non-dilutive capital infusion, representing a substantial portion of the company's market capitalization, has extended Compugen's cash runway into 2029, significantly de-risking its near-term financing needs. While the company announced a decision not to initiate new clinical trials for its COM902 (anti-TIGIT antibody) program due to recent negative data in the broader TIGIT field, it continues to advance other key clinical programs, including COM701 (anti-PVRIG antibody) in a blinded randomized ovarian cancer trial and GS-0321 (anti-IL-18 binding protein antibody) under a license with Gilead. The filing also notes the company's belief that it was classified as a Passive Foreign Investment Company (PFIC) for 2025, which has adverse U.S. federal income tax consequences for U.S. shareholders, and details ongoing geopolitical risks in Israel. This comprehensive annual report follows a 6-K filing on the same day that provided preliminary financial results, adding substantial detail and context to the previously announced figures.